The FDA held a public hearing on September 14th to gather feedback on the potential future therapeutic use of psychedelic drugs in supervised treatment settings. The FDA is interested in topics such as provider training and credentialing, promotion of patient safety, considerations for access, and best practices for data collection and standardization. This hearing aligns with the current Administration’s focus on advancing research into innovative treatments for serious mental health conditions, including post-traumatic stress disorder (PTSD), depression, and substance use disorders, while maintaining FDA standards for safety and effectiveness.
